Silica Glyconanoparticle Production Service
Overview
Silica glyconanoparticles merge the characteristics of silica with the specific recognition abilities of glycans, presenting a broad spectrum of potential uses. The advancement of silica glyconanoparticles is propelled by the demand for sophisticated materials in diverse fields. In biomedicine, they hold great potential for targeted drug delivery, since the glycan components can interact specifically with cell surface receptors, facilitating the precise delivery of therapeutic substances to diseased cells. Furthermore, their application in biosensing is of significant interest, as they can selectively bind to biomarkers, enabling sensitive and specific detection of diseases. In the domain of materials science, silica glyconanoparticles can be integrated into composites to enhance mechanical and functional attributes. They also demonstrate potential in catalysis, where their surface chemistry can be customized to promote specific reactions.
Elevate Your Research with our Superior Silica Glyconanoparticle Production
CD BioGlyco is equipped with an extremely advanced GlycoNano™ Platform and has accumulated rich and profound research experience in the broad and intricate domain of glyconanomics. We are committed to offering a wide and all-encompassing range of glyconanoparticle production services to our esteemed clients. Within this context, we are proficient in fabricating nanoparticles that include but are not restricted to, Carbohydrate-based Nanoparticle, Gold Glyconanoparticle, Silver Glyconanoparticle, Magnetic Glyconanoparticle, Quantum Dot (QD), and silica glyconanoparticles. Our competencies extend to ensuring the accurate synthesis and optimization of these nanoparticles, conforming to the loftiest standards of quality and performance.
Control the Size and Shape of Silica Glyconanoparticle
During the process of synthesizing particles, several factors affect the size and shape of the particles. We control the size of the example by controlling the regulation of reaction conditions, including reaction temperature, reaction time, reactant concentration, etc. For example, a higher reaction temperature and a longer reaction time may increase the particle size, and a lower reactant concentration may facilitate the formation of smaller particles. At the same time, we control the size and shape of the particles by using templates to limit the growth space of the particles, such as mesoporous materials, polymer microspheres, etc. The selection and concentration of suitable surfactants and their concentration also affect the nucleation and growth process of particles, and different types and concentrations of surfactants have different effects on the size and shape of particles.
Characterization of Silica Glyconanoparticle
We characterize the synthesized nanoparticles by various techniques and methods:
- Transmission electron microscopy (TEM): It is used to observe the morphology and structure of the nanoparticles and to confirm their homogeneous pore structure and diameter.
- Dynamic light scattering (DLS): It is used to measure the hydrated diameter of the nanoparticles and to assess their dispersion and particle size distribution in solution.
- Raman spectroscopy: This is used to confirm chemical changes during the functionalization process, such as the appearance and disappearance of thiol absorption peaks, indicating the formation of disulfide bonds.
- Fourier transform infrared spectroscopy (FTIR): It is used to detect the presence of different chemical groups in the functionalized nanoparticles, e.g. characteristic absorption peaks of disulfide bonds.
- Specific surface area analysis (BET): This is used to evaluate the specific surface area and pore size of nanoparticles and confirm the characterization of their porous structure.
Workflow
First, we use an improved synthesis method to synthesize fluorescein isothiocyanate (FITC)-silane by reacting FITC with 3-aminopropyl triethoxysilane. Then, our experts prepared mesoporous silicon nanoparticles with uniform and good mesoporous structure by sol-gel method. Subsequently, the synthesized mesoporous silicon nanoparticles are functionalized. The nanoparticles are thiolated with 3-mercaptopropyl trimethoxysilane to form mercaptol particles (FMSNSH). Subsequently, the particles of perfluorophenyl azide (PFPA) group with disulfide bond are further modified with 2-(pyridine-2-yl disulfide) -ethyl 4-fluorobenzoate (FMSNPFPA). Finally, under ultraviolet light, the nanoparticles are glycosylated. Photoinduced azene chemistry is used to convert PFPA azide groups into azene, which then reacts with glycan to obtain silica glyconanoparticle.

Applications
- Silica glyconanoparticles can be used for drug delivery, where the sugar portion of the surface specifically recognizes the target cell for precise drug delivery.
- Silica glyconanoparticles are doped with fluorescent substances, such as FITC, and can be used for imaging studies of cells and tissues to help track biological processes and disease progression.
- It can be used to build highly sensitive and selective biosensors for detecting biomolecules and pathogens.
Advantages
- We modify and functionalize the glycan groups on the surface according to your needs so that they can specifically interact with biomolecules or cells.
- Our technology allows precise control of particle size, shape, porosity, and surface chemistry to meet the specific needs of different applications.
- The nanoparticles that we synthesize typically exhibit lower biotoxicity and better compatibility with biological systems.
Publication Data
Technologies: Confocal fluorescence microscope, TEM
Journal: Chemical Communications
Published: 2015
IF: 4.31
Results: This article focuses on a novel type of glyconanoparticles designed for drug delivery in response to glutathione. The article describes in detail the synthesis of these nanoparticles, including functionalization, drug loading, and closure processes. Specifically, the researchers achieved control of drug release by binding D-mannose-functionalized porous silica nanoparticles to the anti-cancer drug doxorubicin and using the lectin Con A as a “gating” protein. In drug delivery, the role of these sugar nanoparticles is to trigger drug release through the presence of glutathione. The concentration of glutathione is low in healthy cells and high in cancer cells, so this design allows for selective drug release to cancer cells. It has been shown that glutathione can effectively sever the disulfide bonds in the nanoparticles, thereby unsealing Con A and releasing the drug.
Fig.1 Characterization of FMSN- and FMSN-doxorubicin-ConA. (Zhou, et al., 2015)
Frequently Asked Questions
- How does the surface glycan of the nanoparticles affect its performance and application?
In terms of biometrics, specific glycan can bind specifically to receptors in organisms (such as proteins and cell surface receptors), giving nanoparticles specific targeted recognition capabilities. Hydrophilic, glycol groups are usually hydrophilic, which improves the dispersion and stability of nanoparticles in aqueous solutions. In terms of immune response regulation, certain glycans can regulate the response of the immune system to nanoparticles, reduce immune rejection, and thus improve biocompatibility.
-
How stable is silica glyconanoparticle in vivo?
The stability of the nanoparticles depends to some extent on the particle size, surface chemistry, and the type and density of surface glycol groups. Smaller-sized particles may be more easily cleared by organisms, while larger-sized particles may stay in the bloodstream for longer. Surface chemistry is also crucial for stability. Suitable surface modifications can reduce non-specific interactions with molecules such as proteins in organisms and reduce the risk of phagocytosis by macrophages, thereby improving stability.
CD BioGlyco makes use of cutting-edge technologies and methods to ensure that the produced silica glyconanoparticles display outstanding properties and functionality, fulfilling the diverse and specific demands of our clients. In case you require our service, please feel free to contact us!
Reference
- Zhou, J.; et al. Lectin-gated, mesoporous, photofunctionalized glyconanoparticles for glutathione-responsive drug delivery. Chemical Communications. 2015, 51(48): 9833-9836.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





